CBD triggered autophagy and cell death in amyloid-expressing cells while showing side effects in healthy cells | Research

The takeaway

CBD had contrasting effects depending on disease state: it induced beneficial autophagy and apoptosis in cells expressing Alzheimer's-associated amyloid-beta through LC3B and Caspase-3 pathways, while producing side effects in non-pathological cells. FAAH-1 involvement helped alleviate dysfunction in amyloid-expressing worm models.

Researchers studying CBD for Alzheimer's disease and neurodegenerative conditions.

CBD induced selective autophagy and cell death in amyloid-expressing cells but caused side effects in healthy cells

What the researchers found

CBD induced autophagy and apoptosis specifically in amyloid-beta-expressing cells via LC3B and Caspase-3 pathways, while producing side effects in non-pathological cells. Investigation of CB1 receptors and FAAH showed complex modulation depending on amyloid-beta presence. In C. elegans worm models, FAAH-1 involvement alleviated pharyngeal dysfunction and counteracted weight loss in amyloid-expressing strains.

Why it matters

The finding that CBD has different effects on healthy versus diseased cells is crucial for understanding both its therapeutic potential and safety. If CBD can selectively target amyloid-affected cells while potentially harming healthy ones, this has direct implications for dosing strategies and patient selection in Alzheimer's therapy development.

The numbers in context

CBD induced autophagy via LC3B pathway and apoptosis via Caspase-3 in amyloid-beta-expressing cells. FAAH-1 alleviated pharyngeal dysfunction and counteracted weight loss in amyloid-expressing C. elegans. Effects on CB1 and FAAH differed based on amyloid-beta presence or absence.

How the study worked

Multi-model approach combining pharmacological interventions, immunofluorescence imaging, flow cytometry, and biochemical assays. Effects of CBD on amyloid-beta 40 and 42 were examined, along with modulation of CB1 receptors and FAAH with and without amyloid expression. C. elegans (roundworm) models were used to validate in vivo effects.

What this study cannot tell us

Cell culture and worm models are far from human Alzheimer's disease. The side effects in non-pathological cells raise safety concerns that need characterization. The specific CBD concentrations used may not be achievable in human brains. C. elegans do not have a true brain or amyloid plaques.

How to read the evidence

Multi-model preclinical study combining in vitro cell work with in vivo C. elegans validation, but far from clinical relevance.

When this study was published

Published in 2025.

The bigger picture

This selectivity between healthy and diseased cells aligns with the findings of RTHC-06369 (CBD affecting brain copper differently in healthy vs Alzheimer's mice). Together, these studies suggest CBD's biological effects are context-dependent, potentially beneficial in disease states but not without risks in healthy tissue.

Questions still open

What specific side effects does CBD produce in healthy cells? Can the selective targeting of diseased cells be exploited therapeutically? Does the FAAH pathway represent a druggable target for Alzheimer's? How do these findings translate to mammalian models?

Common questions

Could CBD treat Alzheimer's?

This study shows CBD can target amyloid-beta-affected cells, which is promising. However, the side effects in healthy cells and the enormous gap between cell/worm models and human disease mean much more research is needed.

What are autophagy and apoptosis?

Autophagy is a cellular cleanup process that removes damaged components. Apoptosis is programmed cell death. In Alzheimer's, triggering these in amyloid-affected cells could help clear toxic protein accumulations.

Read the original research

In vivo and In vitro Crosstalk Among CBD, Aβ, and endocannabinoid system enzymes and receptors.

European journal of pharmacology, 1000, 177720

View on PubMed ↗Publisher’s paper ↗

Citation

Duan, Fangyuan; Xiao, Dan; Wang, Jiayu; Li, Runze; Si, Xiaoyue; Lu, Weihong. (2025). In vivo and In vitro Crosstalk Among CBD, Aβ, and endocannabinoid system enzymes and receptors.. European journal of pharmacology, 1000, 177720. https://doi.org/10.1016/j.ejphar.2025.177720